| | |

The Crucial Role of Initial Tests in Mesothelioma Treatment

ByHolly Zink
The Crucial Role of Initial Tests in Mesothelioma Treatment

Mesothelioma diagnosis and treatment begin with a series of initial tests to determine the specific type of the disease. A recent study explored these tests and their accuracy in predicting mesothelioma types.

Discover why getting it right from the start can be a matter of life and death for mesothelioma patients.

Prognosis and Treatment

Mesothelioma is a type of cancer that affects the lining of the lungs and other organs. Doctors often use surgery to remove the cancer. In some cases, they also use chemotherapy before the surgery to shrink the tumor. Before starting treatment, doctors conduct tests to figure out what type of mesothelioma their patient has.

A recent study looked at how accurate the initial tests were in predicting the type of mesothelioma. They also looked at how this affected the survival of patients.

There are three types of mesothelioma that are based on the shape of the cancer cells. One type is called epithelioid, which accounts for about half of mesothelioma cases. This type tends to have a better prognosis than the other two types of mesothelioma.

About 10% of mesotheliomas are sarcomatoid. This type generally has the worst prognosis with standard treatments. The third type of mesothelioma is called mixed or biphasic mesothelioma. This type is made up of both epithelioid and sarcomatoid cells. About 30% to 40% of mesotheliomas are this mixed type.

Challenges of A Complex Diagnosis

The researchers studied 129 patients who had surgery for mesothelioma over five years. They wanted to see if the first tests matched the results after surgery. They also wanted to know how this affected how long the patients lived after the surgery.

They found that in about 21% of cases, the initial assessment didn’t match what they found during surgery. This means that sometimes they thought it was one type of mesothelioma, but it turned out to be a different type. This could be important because different types of mesothelioma may need different treatments.

They also noticed that in some cases where the initial test was wrong, the patients had received chemotherapy before the surgery. This might have caused the cancer to change, making it harder to identify during surgery.

The study showed that patients who had chemotherapy before the surgery and had a wrong initial assessment tended to live for a shorter time after the surgery compared to those who didn’t have chemotherapy. On average, they lived for about 11 months, while those who didn’t have chemotherapy lived for about 19 months after surgery.

The researchers think that giving chemotherapy before surgery might make it harder to predict the type of mesothelioma during surgery correctly. This could lead to worse outcomes for patients.

Because of this, the researchers suggest that for patients whose mesothelioma can be removed with surgery, it might be better to do the surgery first, without chemotherapy. This approach could lead to better outcomes and longer survival for these patients.

Source

Ventura L, Lee M, Baranowski R, Hargrave J, Sheaff M, Waller D. Perioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition? [published online ahead of print, 2023 Oct 18]. Interdiscip Cardiovasc Thorac Surg. 2023;ivad145. doi:10.1093/icvts/ivad145. https://pubmed.ncbi.nlm.nih.gov/37851340/

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…